<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Energy requiring <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and presumably unregulated <z:mp ids='MP_0001651'>necrosis</z:mp> are considered conceptually and morphologically distinct forms of cell <z:hpo ids='HP_0011420'>death</z:hpo> which have been initially identified as two exclusive pathways </plain></SENT>
<SENT sid="1" pm="."><plain>However, several apoptotic characteristics have been observed in the necrotic core lesion in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> which led to the controversial theory that cell <z:hpo ids='HP_0011420'>death</z:hpo> advances via a number of hybrid pathways among a continuum between the two processes </plain></SENT>
<SENT sid="2" pm="."><plain>ATP availability has been shown to influence the decision between <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0001651'>necrosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The aims of our study are 1) to determine if combined inhibitors administration of pan-caspase inhibitor <z:chebi fb="0" ids="51097">Carbobenzoxy</z:chebi>-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk) and non-selective poly (<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase (PARP) inhibitor 3-aminobenzamide (3-AB) can further reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume compared to single modality of either inhibitor following ischemic insult, 2) to ascertain the pharmacological intervention up to 24 hour post-middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo), and 3) to correlate intracellular ATP level with <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="4" pm="."><plain>Single modality treatment was optimised at 3 mg/kg z-VAD-fmk and 30 mg/kg 3-AB with <z:mpath ids='MPATH_124'>infarct</z:mpath> volume measured at 24.13%+/-3.89% and 26.98%+/-2.22% respectively, while untreated control group was determined at 45.97%+/-1.86% </plain></SENT>
<SENT sid="5" pm="."><plain>Combined inhibitors treatment rendered further reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, measuring 7.228%+/-1.988%, 21.02%+/-1.06%, 24.40%+/-2.12% at 30 min, 6 h, 24 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, the combined inhibitors administration of both z-VAD-fmk and 3-AB show further increased in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume reduction with our ischemic model up to the 24 hour post-MCAo </plain></SENT>
<SENT sid="7" pm="."><plain>However, in our in vivo study, no correlation between intracellular ATP level and <z:mpath ids='MPATH_124'>infarct</z:mpath> size was established </plain></SENT>
</text></document>